SMASH: Study to Evaluate the Clinical Efficacy of an Extensively Hydrolysed Infant Formula With Synbiotics and a Human Milk Oligosaccharide (HMO) in Infants With Cow's Milk Protein Allergy (CMPA)

Inclusion Criteria: * Infants under 10 months of age at study start (Visit 1). * Suspected or recently confirmed cow's milk protein allergy (CMPA), as determined by the investigator. * Already formula-fed, or parents/legal guardians have decided to initiate formula feeding. * Inclusion in the study coincides with the first prescription of a hypoallergenic formula. * Written informed consent obtained from parents or legal guardians in accordance with local regulations. Exclusion Criteria: * Infants with functional gastrointestinal symptoms in whom atopy or food allergy is not suspected. * Infants who have previously used an extensively hydrolyzed formula (EHF), an amino acid-based formula (AAF), a rice hydrolysate formula, or a soy-based formula. * Infants who have previously used a partially hydrolyzed formula for the prevention of cow's milk protein allergy (CMPA). * Infants for whom an amino acid-based formula (AAF) is more appropriate as first-line management, including severe forms of CMPA. * Contraindications to the use of synbiotics (e.g., preterm infants \<40 weeks of corrected gestational age at study start, immunodeficiency, short bowel syndrome, parenteral nutrition, post-pyloric feeding, central venous catheter, oncology treatment, or graft-versus-host disease). * Any other condition, as assessed by the investigator, that contraindicates the use of an extensively hydrolyzed formula. * Any other circumstance, as assessed by the investigator, indicating that the parents or legal guardians are not capable of complying with the study procedures.